Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vernon Hoeppner

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Diseases (Basel, Switzerland)|August 27, 2025
Investigating the Relationships Between COVID-19 Cases, Public Health Interventions, Vaccine Coverage, and Mean Temperature in Ontario and TorontoMelinaz Barati Chermahini, Vernon Hoeppner
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 21, 2002
Latent tuberculosis treatmentStan Houston, Richard Long, Vernon Hoeppner
Chest|January 18, 2002
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tubeJohn Reid, Darcy Marciniuk, Charles A Peloquin, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|July 10, 2019
Tuberculosis in Canada and the United States: a review of trends from 1953 to 2015Samuel Kwaku Essien, Tasha Epp, Cheryl Waldner, et al.
Chest|April 3, 2007
The effect of neonatal bacille Calmette-Guérin vaccination on purified protein derivative skin test results in Canadian aboriginal childrenJohn K Reid, Heather Ward, Darcy Marciniuk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2009
Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosisRichard Long, Huey Chong, Vernon Hoeppner, et al.
Canadian Respiratory Journal|May 30, 2013
Marked disparity in the epidemiology of tuberculosis among Aboriginal peoples on the Canadian prairies: the challenges and opportunitiesRichard Long, Vernon Hoeppner, Pamela Orr, et al.
Annals of Internal Medicine|November 20, 2008
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trialDick Menzies, Richard Long, Anete Trajman, et al.
Plos One|November 15, 2017
Tuberculosis transmission in the Indigenous peoples of the Canadian prairiesSmit Patel, Catherine Paulsen, Courtney Heffernan, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Diseases (Basel, Switzerland)|August 27, 2025
Investigating the Relationships Between COVID-19 Cases, Public Health Interventions, Vaccine Coverage, and Mean Temperature in Ontario and TorontoMelinaz Barati Chermahini, Vernon Hoeppner
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 21, 2002
Latent tuberculosis treatmentStan Houston, Richard Long, Vernon Hoeppner
Chest|January 18, 2002
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tubeJohn Reid, Darcy Marciniuk, Charles A Peloquin, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|July 10, 2019
Tuberculosis in Canada and the United States: a review of trends from 1953 to 2015Samuel Kwaku Essien, Tasha Epp, Cheryl Waldner, et al.
Chest|April 3, 2007
The effect of neonatal bacille Calmette-Guérin vaccination on purified protein derivative skin test results in Canadian aboriginal childrenJohn K Reid, Heather Ward, Darcy Marciniuk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2009
Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosisRichard Long, Huey Chong, Vernon Hoeppner, et al.
Canadian Respiratory Journal|May 30, 2013
Marked disparity in the epidemiology of tuberculosis among Aboriginal peoples on the Canadian prairies: the challenges and opportunitiesRichard Long, Vernon Hoeppner, Pamela Orr, et al.
Annals of Internal Medicine|November 20, 2008
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trialDick Menzies, Richard Long, Anete Trajman, et al.
Plos One|November 15, 2017
Tuberculosis transmission in the Indigenous peoples of the Canadian prairiesSmit Patel, Catherine Paulsen, Courtney Heffernan, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
Pageof 2